InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,346.56
(
-1.84%
)
US TECH 100
17,900.00
(
-2.65%
)
Dow Jones
39,737.26
(
-1.51%
)
Brent Oil
77.36
(
0.00%
)
Bitcoin
60,778.77
(
0.17%
)
Post# of 252782
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 120205
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biomaven0 post# 98621

Wednesday, 01/12/2011 8:12:04 AM

Wednesday, January 12, 2011 8:12:04 AM

Post# of 252782
PFE starts NDA submission of Crizotinib in ALK+ NSCLC:

http://finance.yahoo.com/news/Pfizer-Initiates-Rolling-bw-1247799411.html?x=0&.v=1

The rolling submission is expected to be completed during 1H11; with a priority review, Crizotinib could be FDA-approved by the end of 2011.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up